The latest local news, weather and high school sports in and around Columbia and Jefferson City

Our care philosophy is to treat people the way I want to be treated...with care, concern, compassion, and with expertise. We spend a lot of time getting to know our patients, to better take care of their Gastrointestinal and Liver needs.

Clinical Research Studies Going On Now

Listed below are Clinical Trials currently active for enrollment at our site.  If you would like more information on any of the studies, please call our office.

Patients with Crohn’s Disease
Protocol C13007. A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn’s Disease. Rollover Study Available.

Protocol 20090072. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn’s Disease.

Protocol A7281006. A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-00547659 in Subjects with Crohn’s Disease who are Anti-TNF Inadequate Responders (OPERA).

Patients with Ulcerative Colitis (FLARE STATUS)
Protocol SPD476-409. A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis.

Protocol B3041001. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of MultiStem (PF-05285401) in Subjects with Moderate to Severe Ulcerative Colitis.

Patients with Mild to Moderate Ulcerative Proctitis
Protocol CAPSITUP508-01. A Multicenter, Double-Blind, Controlled, Randomized, Parallel Group Comparision Phase IIIA Treatment Investigation of the Efficacy and Safety of MAX-002 Suppository versus Placebo and Active Medication in Mild to Moderate Ulcerative Proctitis.

Patients with Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Protocol BUCF 3001. A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2mg/25mL BID for 2 Weeks, Followed by 2mg/25mL QD for 4 Weeks) versus Placebo in Subjects with Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis.

Patients with Irritable Bowel Syndrome-Diarrhea (IBS-D)
Protocol 27018966IBS2001. A Randomized, Double-blind, Placebo-controlled, Parallel group, Dose ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients with Irritable Bowel Syndrome with Diarrhea.

Protocol MGIB2051. A Phase 2, Randomized, Placebo-controlled, Double-blind Multicenter 12 Week Study to Assess the Efficacy and Safety of Mesalamine Granules 750 MG and 1,500 MG Capsules Administered Once Daily in the Treatment of Irritable Bowel Syndrome with Diarrhea.

Protocol 10LOT01- RELIANCE.  A Phase 4 Research Study to Evaluate LOTRONEX® in Severe IBS-D: Analysis of Current Clinical Practice Environment

Protocol ASMP3001. A 12-Week, Randomized, Double-Blind,Placebo-Controlled Study of Asimadoline in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome.

Patients with Diverticulitis
Protocol SAG-51 DIV. A Double-blind, dose-response, randomized, placebo-controlled, parallel group, multicentre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention of recurrence of diverticulitis.